Matinas BioPharma to Present at the NYC Medical Technology Forum on February 5, 2013
-CEO's Presentation to Outline the Company's 2013 Business Outlook and Key Milestones-
TEWKSBURY, N.J. and TARPON SPRINGS, Fla., Feb. 4, 2013 /PRNewswire/ -- Matinas BioPharma, Inc., a biopharmaceutical company focused on the commercialization and development of omega-3-based prescription therapeutics for the treatment of metabolic and cardiovascular conditions, announced today that Roelof Rongen , Matinas BioPharma's Chief Executive Officer, is scheduled to present at the NYC Medical Technology Forum on Tuesday, February 5, 2013 at 6 PM EST.
Mr. Rongen's presentation will include the Company's business outlook for 2013, an overview of the development of its lead product candidate, MAT9001 and its key milestones expected over the next 12 months. Matinas BioPharma is developing MAT9001 for therapeutic applications, with severe hypertriglyceridemia (TG>500 mg/dL) and mixed dyslipidemia (TG 200-499 mg/dL) as the lead indications. Based on promising early data, the Company is preparing to file an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) and conduct a human study in 2013. Following positive data from this study, Matinas expects to commence its Phase 3 registration program in the first half of 2014.
About Matinas BioPharma
Matinas BioPharma Inc. is a privately-held biopharmaceutical company focused on the development of omega-3-based prescription therapeutics for the treatment of metabolic and cardiovascular conditions. The Company is developing the investigational drug MAT9001 for therapeutic applications with severe hypertriglyceridemia (TG>500 mg/dL) and mixed dyslipidemia (TG 200-499 mg/dL). Matinas is building on its extensive, proprietary research and development capabilities of its founding management team. The Matinas BioPharma team brings a cumulative multi-decade omega-3 pharmaceutical development experience to the Company with a proven track record, providing a unique perspective and capability for the development of the next generation of omega-3-fatty-acid-based pharmaceutical products.
About The NYC Medical Technology Forum (NYC Medtech)
NYC Medtech is a professional platform that assists many different collaborators in the life science, biotech, device and pharma industries have successful outcomes. This unique program not only brings together companies and investors but all people that are involved from reporters, scientists, academia, trade organizations, international partners et. al. The NYC Medtech program introduces its participants with relevant timely introductions whether through the website, email or the personal touch at the NYC Medtech Forum. For more information about the NYC Medical Technology Forum visit www.nycmedtech.com.
Matinas BioPharma, Inc.
SOURCE Matinas BioPharma
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.